bloom retatrutide Urgent warning over illegal weight loss jabs 'not approved for humans' offered for sale on TikTok bloom retatrutide What Are the

The main compound patent protecting the active ingredient semaglutide as used in these three drugs is set to expire in December 2031

Currently, Long-Acting GLP-1 Agonists Occupies the Largest Share of the GLP-1 Market In terms of the type of GLP-1 agonists drugs, the market is segmented into short-acting GLP-1 agonist and long-acting GLP-1 agonist

As of February 2026, 82 percent of U.S

Metabolic goals semaglutide still provides strong benefits for blood sugar and heart health

The article reports nausea in approximately 25 to 44 percent of patients on semaglutide at maintenance doses, and 25 to 33 percent for tirzepatide with vomiting in 1 to 6 percent, depending on dose and the population studied